Our company has developed an innovative platform technology, named “Avatiome,” to identify the best drug candidates, confirm Immuno-modulatory properties in germ-free mice systems, define effective molecules, and elucidate mechanisms of action of related products. Furthermore, by employing humanized mouse model containing human immune cell components and microbiota, we evaluate the translational possibilities of utilizing preclinical data for clinical applicability. 

​

One of our strong research capabilities is to define the effector molecules that recapitulate the functionalities of LBP and elucidate their mechanisms of action, which enable us to design an optimal combination of drug candidates with our LBP candidates. Accordingly, we have been attracting global attention by publishing many articles in prestigious academic journals, including Science Immunology, Immunity, and Nature Communications.

​

ImmunoBiome will leap forward as an innovative new drug development company to cure intractable diseases like cancer and autoimmune diseases based on our solid scientific research.